Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2 at Annual Meeting 2018
PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2
